The share of Cannovum AG has been included in trading on the Xetra and Frankfurt Stock Exchange. This means that Cannovum AG is now represented on Germany's largest and most important stock exchange.
Cannovum AG enters into a partnership with WEECO Pharma GmbH. As of today, Cannovum will include WEECO's products in its portfolio, taking another important step towards becoming a full-service cannabis provider.
Cannovum AG, the first German fully licensed cannabis company on the stock exchange, will move on Dec. 1st 2022 from the Open Market to the "Primary Market" segment of the Düsseldorf Stock Exchange.
Cannovum AG expands its Management Board. The new board position of the first German fully licensed cannabis company on the stock exchange will be taken over by Klaus Madzia as of 25.11.2022.
Cannovum AG, one of the market leaders in the medical cannabis market, welcomes progress on the legalization of cannabis.
Cannovum AG launches the first research project on the future of investor communication with the renowned Macromedia University.
Cannovum AG significantly increased both sales and customers in its medical cannabis business in H1 2022.
Cannovum AG has participated in the consultation process of the German government for the legalization of cannabis for Adult-use.
The Management Board of Cannovum AG today resolved to increase the share capital.
Cannovum Medical Education (CME) is a free, comprehensive virtual continuing education platform for medical cannabis, in which the medical-therapeutic basics of medical cannabis are scientifically prepared.
From now on, delivery to every pharmacy throughout Germany will take place directly on the next working day if the order is placed by 12:30 pm.
Following the coalition agreement, Cannovum AG will enter into the recreational cannabis market. The present offer in the field of medical cannabis will be maintained and further expanded.
This is an extension of the wholesale permit and allows the trade of active ingredients. One of the main active ingredients of cannabis is THC, which is considered to have the greatest pharmaceutical potential and therapeutic efficacy.
Priv. Doz. Dr. med. habil. Philipp Sewerin is the new member of the supervisory board as well as the Medical Advisory Board. Dr. Sewerin is a specialist in internal medicine and rheumatology at the university clinic in Düsseldorf.
Cannovum took the first step and founded Cannovum Iberia LDA, a joint venture between Cannovum and Portuguese entrepreneurs from the cannabis industry.
Cannovum has signed a supply agreement for full-spectrum cannabis extracts. The extracts are distributed to pharmacies under Cannovum's own brand.
Cannovum has entered into a long term supply agreement with Aurora Europe. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.
Cannovum is pleased to announce a strategic supply partnership for Dronabinol with a European medical cannabis supplier. Products are expected to be sold starting from August as part of the Cannovum brand range.
First German medical cannabis company listed on the German stock exchange: shares in Cannovum AG can now be traded on the OTC market of the Düsseldorf Stock Exchange.
Our CEO, Pia Marten, spoke with Krautinvest about Cannovum’s unique place on the German market as the first medical cannabis company to employ this sustainable approach to their own product line.
We are excited to announce our partnership with the BPC, who promote sustainable development of cannabinoid therapies and strengthen the legitimacy of the pharmaceutical cannabinoid industry.
Handelsblatt published an entrepreneur profile that covers the motivation of our CEO Pia Marten behind founding Cannovum AG. Find the article here:
With the market entry and the launch of our online shop, Cannovum takes a big step forward to further improve the supply of patients with cannabinoid-based therapies.
Sandra has 15 years of experience in the healthcare industry and has led the development of the medical affairs department and the education platform "Aurora Academy" for the Canadian manufacturer Aurora.
Our CEO Pia Marten met Friedrich Merz and other entrepreneurs in Berlin. The discussion focused on topics like digitalization, entrepreneurship, and promotion of innovation.
This means we can streamline our supply chain by packaging and labeling in Germany.
We are pleased to announce that Dr. med. Dipl.-Chem. Konrad F. Cimander will support us with his expertise in the field of medical cannabis. Learn more about Dr. Cimander on our Medical Advisory Board:
We are now a fully licensed pharmaceutical wholesaler and ready to make our vision come true! Find our licenses here:
Cannovum AG has moved to Factory Berlin. We are looking forward to meeting many more innovative companies and expanding our network.
Cannovum performed a successful GMP audit of its first supplier. We ensure that our cultivators adhere to strict EU GMP regulations, highest standards and quality.
Pia has released an english translation of her well received Krautinvest.de article. Read about her insights from the BfArM survey on Medium:
Our CEO and Co-Founder has studied the most comprehensive data on cannabis patients in Germany and shared her insights on Krautinvest.de:
Cannovum reached another milestone! We were granted the pharmaceutical wholesale license (§52a AMG). See our license below:
We're happy to be part of the network that connects the cannabis industry in Germany and Europe! Learn more about the BvCW on their website:
We're proud to announce that we're now an official supporting member of the "VCA", the German association for cannabis dispensing pharmacies.